비교리스트

 카트 문의
시장보고서
상품코드
1514123

세계의 편두통 치료제 시장

Migraine Drugs
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 193 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

편두통 치료제 시장은 2030년까지 92억 달러에 도달할 것으로 예측됩니다.

2023년에 32억 달러로 평가된 편두통 치료제 시장은 예측 기간 동안 복합 연간 성장률(CAGR) 16.1%로 성장하여, 2030년에는 92억 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 급성 치료는 복합 연간 성장률(CAGR) 16.7%로 성장을 지속하고, 분석 기간 종료 시 72억 달러에 달할 것으로 예측됩니다. 예방 치료 부문의 성장률은 분석 기간 동안 복합 연간 성장률(CAGR) 14.2%로 추정됩니다.

미국 시장은 8억 7,330만 달러로 추정되며 중국은 복합 연간 성장률(CAGR) 21.6%로 성장할 것으로 예측됩니다.

미국의 편두통 치료제 시장은 2023년 8억 7,330만 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 22억 달러 규모에 이를 것으로 예측되며 예측 기간 동안 복합 연간 성장률(CAGR) 21.6%입니다. 다른 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 복합 연간 성장률(CAGR) 각각 11.7%와 13.6%로 예측되고 있습니다. 유럽에서는 독일이 복합 연간 성장률(CAGR) 약 12.6%로 성장할 것으로 예측됩니다.

세계 편두통 치료제 시장 - 주요 동향과 촉진요인 요약

편두통 치료제는 종종 메스꺼움, 구토, 빛과 소리에 대한 과민증을 동반하는 심한 두통의 재발을 특징으로 하는 쇠약성 신경 증상인 편두통의 관리 및 치료에 필수적입니다. 이 약은 편두통 발작시 증상을 완화하는 급성 치료와 발작의 빈도와 중증도를 완화하는 예방 치료로 크게 나뉩니다. 급성 치료제에는 트립탄계 약제, 에르고타민계 약제, 비스테로이드성 항염증제(NSAIDs) 등이 있으며, 예방 치료제에는 β차단제, 항경련제, 새로운 분류의 칼시토닌 유전자 관련 펩티드(CGRP) 저해 약 등이 있습니다. 엘레누맙, 프레마네주맙, 갈카네주맙과 같은 CGRP 억제제는 편두통의 병태생리학에서 중요한 역할을 하는 CGRP 경로를 표적으로 함으로써 편두통 예방에 혁명을 가져왔습니다. 이러한 표적 치료제를 이용할 수 있게 됨으로써, 종래의 약물 요법은 완화가 제한된 많은 편두통 환자의 삶의 질을 크게 향상시켰습니다.

편두통 치료제 시장은 편두통의 유병률 증가와 이 증상이 삶의 질에 미치는 영향에 대한 의식이 높아짐에 따라 빠르게 확대되고 있습니다. 세계보건기구(WHO)에 따르면, 편두통은 세계 신체장애의 주요 원인 중 하나이며, 추정 10억명이 이환하고 있습니다. 이러한 높은 유병률로 인해 효과적인 편두통 관리 전략의 필요성이 강조되고, 이 분야의 연구 개발에 박차가 걸리고 있습니다. 제약회사는 차세대 CGRP 억제제와 효능을 높이고 부작용을 줄이는 병용요법 등 신규 편두통 치료제 개발에 많은 투자를 하고 있습니다. 또한 모바일 앱과 웨어러블 디바이스를 이용하여 편두통을 모니터링하고 관리하는 디지털 치료제의 도입은 개별화된 편두통 치료의 중요한 발전입니다. 이러한 디지털 도구를 사용하면 환자가 증상, 유인 및 약물 사용을 추적할 수 있어 보다 정확하고 효과적인 치료 계획을 수립할 수 있습니다.

편두통 치료제 시장의 성장은 의약품 개발의 기술 진보, 맞춤형 의료에 대한 수요 증가, 만성 편두통 유병률 증가 등 여러 요인에 의해 야기됩니다. 기술 혁신은 편두통의 예방과 치료를 일변시킨 CGRP 억제제 등 보다 효과적이고 치밀한 치료법의 개발로 이어졌습니다. 또한 맞춤형 의료에 대한 수요 증가도 시장을 뒷받침하고 있으며 환자는 특정 유전적 요인과 생활 방식에 맞는 치료를 요구하고 있습니다. 게다가 세계 인구의 상당 부분이 앓고 있는 만성 편두통의 유병률 증가는 효과적인 편두통 치료에 대한 큰 수요를 낳고 있습니다. 신흥 시장의 건강 관리 인프라 확장과 첨단 편두통 치료에 대한 접근성 증가는 시장 성장을 더욱 촉진하고 있습니다. 또한, 편두통과 그 치료법에 대한 인식과 교육 증가는 환자에게 의료 지원을 요구하는 힘을 주고 편두통 치료제 수요를 촉진하고 있습니다. 이러한 요인은 종합적으로 편두통 치료제 시장의 견조한 성장에 기여하고 있으며, 의학 연구의 지속적인 발전과 세계 편두통 환자의 요구의 진화를 반영합니다.

조사 대상 기업 예(전 59건)

  • Allergan PLC
  • Amgen, Inc.
  • Biohaven Pharmaceutical Holding Company Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

BJH 24.07.25

Global Migraine Drugs Market to Reach US$9.2 Billion by 2030

The global market for Migraine Drugs estimated at US$3.2 Billion in the year 2023, is expected to reach US$9.2 Billion by 2030, growing at a CAGR of 16.1% over the analysis period 2023-2030. Acute Treatment, one of the segments analyzed in the report, is expected to record a 16.7% CAGR and reach US$7.2 Billion by the end of the analysis period. Growth in the Preventive Treatment segment is estimated at 14.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$873.3 Million While China is Forecast to Grow at 21.6% CAGR

The Migraine Drugs market in the U.S. is estimated at US$873.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 21.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.7% and 13.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.6% CAGR.

Global Migraine Drugs Market - Key Trends and Drivers Summarized

Migraine drugs are critical in the management and treatment of migraines, a debilitating neurological condition characterized by intense, recurrent headaches often accompanied by nausea, vomiting, and sensitivity to light and sound. These medications are broadly categorized into acute treatments, which alleviate symptoms during a migraine attack, and preventive treatments, which reduce the frequency and severity of attacks. Acute treatments include triptans, ergotamines, and nonsteroidal anti-inflammatory drugs (NSAIDs), while preventive treatments encompass beta-blockers, anticonvulsants, and the newer class of calcitonin gene-related peptide (CGRP) inhibitors. CGRP inhibitors, such as erenumab, fremanezumab, and galcanezumab, have revolutionized migraine prevention by targeting the CGRP pathway, which plays a crucial role in migraine pathophysiology. The availability of these targeted therapies has significantly improved the quality of life for many migraine sufferers who previously found limited relief with traditional medications.

The global market for migraine drugs has expanded rapidly, driven by the increasing prevalence of migraines and the growing awareness of the condition's impact on quality of life. According to the World Health Organization, migraines are one of the leading causes of disability worldwide, affecting an estimated one billion people. This high prevalence has underscored the need for effective migraine management strategies and spurred research and development in this field. Pharmaceutical companies are investing heavily in the development of novel migraine therapies, including next-generation CGRP inhibitors and combination therapies that offer enhanced efficacy and reduced side effects. Additionally, the introduction of digital therapeutics, which utilize mobile apps and wearable devices to monitor and manage migraines, represents a significant advancement in personalized migraine care. These digital tools enable patients to track their symptoms, triggers, and medication usage, facilitating more precise and effective treatment plans.

The growth in the migraine drugs market is driven by several factors, including technological advancements in drug development, increasing demand for personalized medicine, and the rising prevalence of chronic migraines. Technological innovations have led to the development of more effective and targeted therapies, such as CGRP inhibitors, which have transformed migraine prevention and treatment. The increasing demand for personalized medicine has also propelled the market, as patients seek treatments tailored to their specific genetic and lifestyle factors. Additionally, the rising prevalence of chronic migraines, which affect a significant portion of the global population, has created a substantial demand for effective migraine treatments. The expansion of healthcare infrastructure in emerging markets and the growing accessibility of advanced migraine therapies have further fueled market growth. Furthermore, increased awareness and education about migraines and their treatment options have empowered patients to seek medical help, thereby driving the demand for migraine drugs. These factors collectively contribute to the robust growth of the migraine drugs market, reflecting the ongoing advancements in medical research and the evolving needs of migraine sufferers worldwide.

Select Competitors (Total 59 Featured) -

  • Allergan PLC
  • Amgen, Inc.
  • Biohaven Pharmaceutical Holding Company Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Migraine Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Chronic Migraines Expands Addressable Market Opportunity
    • Advances in CGRP Inhibitors Propel Growth in Migraine Treatment
    • Increasing Demand for Personalized Medicine Spurs Adoption of Tailored Therapies
    • Innovations in Digital Therapeutics Strengthen Business Case for Migraine Management
    • Growing Awareness of Migraine Impact on Quality of Life Drives Market Expansion
    • Technological Innovations in Drug Delivery Systems Propel Growth
    • Introduction of Combination Therapies Accelerates Demand for Migraine Drugs
    • Increased Investment in Migraine Research and Development Spurs Market Innovation
    • Focus on Reducing Side Effects and Improving Efficacy Drives Adoption of New Therapies
    • Consumer Preference for Non-Pharmacological Treatments Throws the Spotlight on Alternative Therapies
    • Rising Healthcare Expenditure Sustains Growth in Migraine Drugs Market
    • Growth of Telemedicine and Remote Monitoring Expands Accessibility to Migraine Care
    • Focus on Long-Term Preventive Treatments Expands Addressable Market
    • Increasing Prevalence of Lifestyle-Related Triggers Strengthens Business Case for Migraine Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Migraine Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Migraine Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Migraine Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Migraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Acute Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Acute Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Acute Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Preventive Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Preventive Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Preventive Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Triptans by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Triptans by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Triptans by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Acetylcholine Inhibitors / Neurotoxins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Acetylcholine Inhibitors / Neurotoxins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Acetylcholine Inhibitors / Neurotoxins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Ergot Alkaloids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Ergot Alkaloids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Ergot Alkaloids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other Therapeutic Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Route of Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Route of Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Other Route of Administrations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • JAPAN
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • CHINA
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • EUROPE
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Migraine Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Migraine Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Migraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • FRANCE
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • GERMANY
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Migraine Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Migraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • INDIA
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: India 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Migraine Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Migraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Migraine Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Migraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030
  • AFRICA
    • Migraine Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2014, 2024 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors / Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2014, 2024 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2014, 2024 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제